Peter A. Thompson - 10 Jun 2021 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: Director, 10%+ Owner
Signature: /s/ Tighe Reardon, Attorney-in-Fact
Issuer symbol: JANX
Transactions as of: 10 Jun 2021
Transactions value $: $0
Form type: 4
Filing time: 14 Jun 2021, 17:43:44 UTC
Previous filing: 21 Sep 2021
Next filing: 16 Jun 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JANX	Stock Option (right to buy)	Award	$0	+30K		$0.00	30K	10 Jun 2021	Common Stock	30K	$17.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option will vest in equal monthly installments over the 36 months following June 10, 2021.
F2	Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.

Content

The shares subject to the option will vest in equal monthly installments over the 36 months following June 10, 2021.

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.